Significance of stromal decorin expression during the progression of breast cancer

Oda,Goshi; Sato,Takanobu; Ishikawa,Toshiaki; Kawachi,Hiroshi; Nakagawa,Tsuyoshi; Kuwayama,Takashi; Ishiguro,Megumi; Iida,Satoru; Uetake,Hiroyuki; Sugihara,Kenichi

doi:10.3892/or.2012.2040

Significance of stromal decorin expression during the progression of breast cancer

Authors:
- Goshi Oda
- Takanobu Sato
- Toshiaki Ishikawa
- Hiroshi Kawachi
- Tsuyoshi Nakagawa
- Takashi Kuwayama
- Megumi Ishiguro
- Satoru Iida
- Hiroyuki Uetake
- Kenichi Sugihara
View Affiliations

Affiliations: Department of Surgical Oncology, Tokyo Medical and Dental University, Graduate School of Medicine and Dentistry, Bunkyo-ku, Tokyo 113-8519, Japan, Department of Translational Oncology, Tokyo Medical and Dental University, Graduate School of Medicine and Dentistry, Bunkyo-ku, Tokyo 113-8519, Japan, Department of Pathology, Tokyo Medical and Dental University, Graduate School of Medicine and Dentistry, Bunkyo-ku, Tokyo 113-8519, Japan
Published online on: September 17, 2012 https://doi.org/10.3892/or.2012.2040
Pages: 2003-2008

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Decorin, a small leucine-rich proteoglycan and important component of the extracellular matrix (ECM), is a natural anticancer agent that modulates several receptors involved in cell growth and survival. Reductions in decorin expression may weaken the ECM and enhance the effectiveness of these receptors and may, consequently, lead to tumor spreading. To determine the contribution of stromal decorin regulation in the development of breast cancer and in tumor invasiveness, immunohistochemistry was used to examine the expression of stromal decorin in 120 breast cancer tissue samples. In patients with invasive breast carcinoma (IBC), stromal decorin expression was highest in normal gland tissue, lower in in situ components and the lowest in invasive components. Stromal decorin expression adjacent to malignant cells in IBC tumors was also significantly weaker compared to that in pure ductal carcinoma in situ (DCIS). These findings indicate that there is a striking difference in the stromal decorin expression around normal glands and around DCIS or IBC tumors. Reduced levels of decorin were associated with more aggressive disease; this finding was consistent with the view that reduced decorin expression may facilitate tumorigenesis, tumor invasion and/or tumor growth. Given these and other reported findings, evaluating stromal decorin expression may be useful in assessing prognosis and malignant potential; therefore, a large-scale study of decorin expression is warranted.

View Figures

View References

1	Kim SH, Turnbull J and Guimond S: Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 209:139–151. 2011. View Article : Google Scholar : PubMed/NCBI
2	Goldoni S and Iozzo R: Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer. 123:2473–2479. 2008. View Article : Google Scholar : PubMed/NCBI
3	Iozzo R: Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 67:609–652. 1998. View Article : Google Scholar : PubMed/NCBI
4	Reed CC and Iozzo RV: The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 19:249–255. 2002. View Article : Google Scholar : PubMed/NCBI
5	Yamaguchi Y, Mann D and Ruoslahti E: Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature. 346:281–284. 1990. View Article : Google Scholar : PubMed/NCBI
6	Araki K, Wakabayashi H, Shintani K, et al: Decorin suppresses bone metastasis in a breast cancer cell line. Oncology. 77:92–99. 2009. View Article : Google Scholar : PubMed/NCBI
7	Goldoni S, Seidler D, Heath J, et al: An antimetastatic role for decorin in breast cancer. Am J Pathol. 173:844–855. 2008. View Article : Google Scholar : PubMed/NCBI
8	Burstein HJ, Polyak K, Wong JS, Lester SC and Kaelin CM: Ductal carcinoma in situ of the breast. N Engl J Med. 350:1430–1441. 2004. View Article : Google Scholar : PubMed/NCBI
9	Sobin LH and Wittekind C: TNM Classification of Malignant Tumors. 6th edition. John Wiley & Sons; New York: 2002
10	Augoff K, Grabowski K, Rabczynski J, Kolondra A, Tabola R and Sikorski A: Expression of decorin in esophageal cancer in relation to the expression of three isoforms of transforming growth factor-beta (TGF-beta1, -beta2, and -beta3) and matrix metalloproteinase-2 activity. Cancer Invest. 27:443–452. 2009. View Article : Google Scholar : PubMed/NCBI
11	Augoff K, Rabczynski J, Tabola R, Czapla L, Ratajczak K and Grabowski K: Immunohistochemical study of decorin expression in polyps and carcinomas of the colon. Med Sci Monit. 14:CR530–CR535. 2008.PubMed/NCBI
12	Ferdous Z, Wei V, Iozzo R, Höök M and Grande-Allen K: Decorin-transforming growth factor-interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem. 282:35887–35898. 2007. View Article : Google Scholar
13	Ständer M, Naumann U, Dumitrescu L, et al: Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 5:1187–1194. 1998.PubMed/NCBI
14	Reiss M and Barcellos-Hoff MH: Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat. 45:81–95. 1997. View Article : Google Scholar : PubMed/NCBI
15	Akhurst RJ and Balmain A: Genetic events and the role of TGF beta in epithelial tumour progression. J Pathol. 187:82–90. 1999. View Article : Google Scholar : PubMed/NCBI
16	Iozzo R, Moscatello D, McQuillan D and Eichstetter I: Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem. 274:4489–4492. 1999. View Article : Google Scholar : PubMed/NCBI
17	Csordás G, Santra M, Reed C, et al: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem. 275:32879–32887. 2000.PubMed/NCBI
18	Polette M, Gilbert N, Stas I, et al: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 424:641–645. 1994. View Article : Google Scholar : PubMed/NCBI
19	Imai K, Hiramatsu A, Fukushima D, Pierschbacher M and Okada Y: Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 322:809–814. 1997.PubMed/NCBI
20	Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N and Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 87:602–611. 1996. View Article : Google Scholar : PubMed/NCBI
21	Jones JL, Glynn P and Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 189:161–168. 1999. View Article : Google Scholar : PubMed/NCBI
22	Garbett EA, Reed MW, Stephenson TJ and Brown NJ: Proteolysis in human breast cancer. Mol Pathol. 53:99–106. 2000. View Article : Google Scholar
23	Jiang WG, Davies G, Martin TA, et al: Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res. 11:6012–6019. 2005. View Article : Google Scholar : PubMed/NCBI
24	Quante M, Tu SP, Tomita H, et al: Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 19:257–272. 2011. View Article : Google Scholar : PubMed/NCBI
25	Matsumine A, Shintani K, Kusuzaki K, et al: Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol. 96:411–418. 2007. View Article : Google Scholar : PubMed/NCBI
26	Troup S, Njue C, Kliewer E, et al: Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res. 9:207–214. 2003.PubMed/NCBI